NIH R01 · 2025
AMPA Receptor Components of the Antidepressant Response to Ketamine in Humans
Project Summary Treatment resistant depression (TRD) is a major cause of distress and disability. The discovery of the antidepressant effects of ketamine, an N -Methyl- D -aspartate glutamate receptor (NMDAR) antagonist, has brought new hope to TRD patients. The search for the biological bases underlying the antidepressant effects of ketamine is a key priority. Preclinical studies suggest that, in the subcallosal cortex (SCC), ketamine activates cortical circuits, increasing glutamate release, stimulating α-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid glutamate receptors (AMPAR), and engaging downstream neuroplasticity mechanisms. In animal models of depression, AMPAR blockade…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.